Abstract:Objective Glucocorticoid (GC) excess decreases bone mineralization and microarchitecture and lead to reduced bone strength. Both anabolic agent parathroid hormone (PTH) and anti-resorptive agent alendronate (ALN) are used to prevent and treat GC-induced bone loss, yet these bone active agents alter bone turnover by very different mechanisms. Our study was to determine how PTH and ALN alter bone quality following GC excess.Methods Nine-month-old SD male rats were treated with methylprednisolone (5 mg/kg·d) or placebo (CON). Other two groups of GC-treated rats had either PTH(80 μg/kg·d) or ALN(4 mg/kg·d) intervention. All the animals were killed after 3 months, and femur and tibia isolated for indicated detection. Bone quality and quantity measurements were measured by dual x-ray absorptiometry (DEXA) for the degree of bone mineralization, histomorphometry for bone microarchitecture, biochemistry for bone turnover. Osteoblasts isolated from newborn rats were cultured in vitro. Cells were treated with 1) CON: placebo; 2)GC: Dexamethasone 10-5mol/L; 3) ALN: Alendronate 10-7mol/L; 4)PTH: human recombinant parathyroid hormone 10-7mol/L; 5)GC+ALN: Dexamethasone 10-5mol/L+ALN 10-7mol/L; 6)GC+PTH: Dexamethasone 10-5mol/L+ PTH 10-7mol/L. Osteoblast proliferation and osteogenic activity were identified by MTT, alkaline phosphatase detection, calcium nodules were observed by Alizarin red staining, and real-time PCR were performed to monitor the expression of several key genes regulating bone formation and mineralization as FGF23 and SOST.Results Spine and Femur BMD was reduced after GC treatment, and it was restored to CON level with GC+ALN and GC+PTH at site of femur and spine separately (P<0.05). Compared to the CON, GC treatment decreased trabecular bone volume, bone formation rate, mineral apposition rate and serum BGP, but increased osteoclast surface and serum TRAP5b (P<0.05). GC+PTH increased and GC+ALN restored trabecular bone volume to the CON levels (P<0.05 compared to GC). GC+PTH increased bone formation rate and serum BGP compared to GC (P<0.05), while GC+ALN increased mineral apposition rate (P<0.01) and reduced osteoclast surface and serum TRAP5b compared to GC (P<0.05). As to osteoblasts experiments, GC treatment decrease MTT and AKP activity, reduced calcium nodules significantly (P<0.05 compared to CON), however, GC+PTH and GC+ALN promoted osteoblast MTT and AKP to the CON levels, but PTH significantly inhibited the calcium nodules, whereas ALN increased it. Realtime-PCR revealed that SOST and FGF23 were up-regulated by GC treatment (P<0.05 compared to CON), but SOST gene was down-regulated after GC+PTH treatment (P<0.01 compared to GC), while SOST and FGF23 genes were both down-regulated by GC+ALN treatment (P<0.05 compared to GC). Conclusion GC excess increased expression of gene that inhibit osteoblast activity and gene that inhibit mineralization and which were associated with reduced bone formation and bone volume. The addition of both PTH and ALN improved bone mass and bone strength during concurrent GC treatment, with PTH lowering expression of SOST and increasing bone formation; while ALN lowered the expression of SOST and FGF23 and reversed the deterioration of bone mineralization induced by GC excess.

Glucocorticoids Activate the Local Renin–angiotensin System in Bone: Possible Mechanism for Glucocorticoid-Induced Osteoporosis

Local renin-angiotensin system is associated with bone mineral density of glucocorticoid-induced osteoporosis patients

Investigation on the Role on Perindopril for Prevention and Treatment of Glucocorticoid Induced Osteoporosis in Rab-Bits

Influence of Glucocorticoids on the Osteogenic Differentiation of Rat Bone Marrow-Derived Mesenchymal Stem Cells

Role of the Local Bone Renin-Angiotensin System in Steroid-Induced Osteonecrosis in Rabbits

Regulatory effects of glucocorticoids on the local renin-angiotensin system in osteoblasts

In vivo and in vitro action mechanism of treatment of glucocorticoid-induced osteoporosis by regulation of osteoprotegerin/receptor activator of nuclear factor-κB pathways by denshensu

[The effects of glucocorticoid on expression of cannabinoid-1 receptors in osteoclasts from tibial proximal metaphysis of rats].

Ortho-silicic Acid Plays a Protective Role in Glucocorticoid-Induced Osteoporosis Via the Akt/Bad Signal Pathway in Vitro and in Vivo.

[Pathogenesis of glucocorticoid-induced osteoporosis based on label-free mass proteomics]

Effect of Reinforcing Kidney to Replenish Marrow Herbs Compound on mRNA and Protein Expression of Osterix in Kidney Tissues of Rats with Glucocorticoid-Induced Osteoporosis

Immunolocalization of MMP 2, 9 and 13 in prednisolone induced osteoporosis in mice.

Galangin mitigates glucocorticoid-induced osteoporosis by activating autophagy of BMSCs via triggering the PKA/CREB signaling pathway

Glucocorticoid-induced Expansion of Classical Monocytes Contributes to Bone Loss

EFFECT OF GLUCOCORTICOID ON EXPRESSION LEVELS OF OSTEOPROTEGERINIRECEPTOR ACTIVATOR OF NUCLEAR FACTOR KAPPA B LIGAND-MATRIX METALLOPROTEINASE/TISSUE INHIBITOR OF MATRIX METALLOPROTEINASE SYSTEM IN BONE TISSUES OF FEMORAL HEAD OF RATS

Comparative Investigation of Effect of Reinforcing Kidney,strengthening Spleen and Promoting Blood Circulation Herbs on Mrna and Protein Expression of Osterix in Bone Tissue of Rats with Glucocorticoid-Induced Osteoporosis

Experimental Studies on Expressions of OPG/RANKL mRNA and Protein of Bone tissue in Kidney Deficiency Rats with Osteoporosis Induced by Glucocorticoid

Potential therapeutic targets of alendronate and PTH for glucocorticoid-induced bone loss

Strontium gluconate potently promotes osteoblast development and restores bone formation in glucocorticoid-induced osteoporosis rats

Effect of long-term administration of glucocorticoid on expression level of OPG/RANKL mRNAs in bone tissues of femoral head of rats

IGF-1 reverses the osteogenic inhibitory effect of dexamethasone on BMP9-induced osteogenic differentiation in mouse embryonic ﬁbroblasts via PI3K/AKT/COX-2 pathway